padnarsertib (KPT-9274) / Karyopharm, Antengene  >>  Phase 1
Welcome,         Profile    Billing    Logout  

3 Trials

Remove FilterRemove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
padnarsertib (KPT-9274) / Karyopharm
PANAMA, NCT02702492: PAK4 and NAMPT in Patients With Solid Malignancies or NHL

Terminated
1
60
Canada, US
KPT-9274, Niacin ER, Nivolumab, Opdivo®
Karyopharm Therapeutics Inc
Solid Tumors, NHL
02/21
06/21
TEACH, NCT04281420: A Study of Evaluating Dual Inhibitor of PAK4 and NAMPT ATG-019 in Advanced Solid Tumors or Non-Hodgkin's Lymphoma

Terminated
1
20
RoW
ATG-019, KPT-9274, ATG-019 + Niacin ER
Antengene Therapeutics Limited
Solid Tumor, Non-Hodgkin's Lymphoma
10/23
10/23
NCT04914845: KPT-9274 in Patients With Relapsed and Refractory Acute Myeloid Leukemia

Recruiting
1
40
US
KPT-9274
University of Colorado, Denver, Karyopharm Therapeutics Inc
Acute Myeloid Leukemia, Acute Myeloid Leukemia, in Relapse, Acute Myeloid Leukemia Refractory
02/26
02/27

Download Options